{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:33:04Z","timestamp":1792009984464,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.vaccine.2015.11.057","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T12:04:04Z","timestamp":1450267444000},"page":"875-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Clinical experience with the meningococcal B vaccine, Bexsero \u00ae : Prospects for reducing the burden of meningococcal serogroup B disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Philip S.","family":"Watson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.11.057_bib0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.11.057_bib0315","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.057_bib0320","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meninogococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0325","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/eri.13.42","article-title":"The burden and impact of severe and long-term sequelae of meningococcal disease","volume":"11","author":"Vyse","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0330","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1871526515999150320155614","article-title":"Complications of serogroup B meningococcal disease in survivors: a review","volume":"14","author":"Dastouri","year":"2015","journal-title":"Infect Disord Drug Targets"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.057_bib0335","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1904.111799","article-title":"Description and nomenclature of Neisseria meningitidis capsule locus","volume":"19","author":"Harrison","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0340","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe. Available from \u3008http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/invasive-bacterial-diseases-surveillance-2011.pdf\u3009; 2012 [accessed 18.03.15]."},{"key":"10.1016\/j.vaccine.2015.11.057_bib0345","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis. Available from \u3008http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening08.pdf\u3009; 2008 [accessed 18.03.15]."},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.057_bib0350","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/erv.13.30","article-title":"Controlling serogroup B invasive meningococcal disease: the Canadian perspective","volume":"12","author":"Bettinger","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"9580","key":"10.1016\/j.vaccine.2015.11.057_bib0355","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.11.057_bib0360","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.057_bib0365","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/JCM.06835-11","article-title":"Invasive serogroup B Neisseria meningitidis in Quebec, Canada 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003","volume":"50","author":"Zhou","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"9431","key":"10.1016\/j.vaccine.2015.11.057_bib0370","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.057_bib0375","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccine","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.057_bib0380","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciu597","article-title":"The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012","volume":"59","author":"Sadarangani","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.11.057_bib0385","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2015.11.057_bib0390","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1469-0691.2012.03939.x","article-title":"Developing vaccines in the era of genomics: a decade of reverse vaccinology","volume":"18","author":"Seib","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.057_bib0395","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/hv.18500","article-title":"Bexsero: a multicomponent vaccine for prevention of meningococcal disease","volume":"8","author":"Gorringe","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0400","unstructured":"Bexsero meningococcal group B vaccine for injection in pre-filled syringe. Summary of product characteristics. Available from \u3008https:\/\/www.medicines.org.uk\/emc\/medicine\/28407\/SPC\/Bexsero+Meningococcal+Group+B+vaccine+for+injection+in+pre-filled+syringe\/#INDICATIONS\u3009. [accessed 19.03.15]."},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.057_bib0405","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.057_bib0410","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"9869","key":"10.1016\/j.vaccine.2015.11.057_bib0415","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2015.11.057_bib0420","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0425","unstructured":"Bexsero Canadian Product Monograph. Available from \u3008http:\/\/www.novartis.ca\/asknovartispharma\/download.htm?res=bexsero_scrip_e.pdf&resTitleId=870\u3009 [accessed 10.06.15]."},{"key":"10.1016\/j.vaccine.2015.11.057_bib0430","unstructured":"Bexsero USA Prescribing Information. Available from \u3008https:\/\/www.novartisvaccinesdirect.com\/pdf\/Bexsero_PI.pdf\u3009 [accessed 10.03.15]."},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.057_bib0435","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1017\/S095026881300294X","article-title":"Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK","volume":"142","author":"Huels","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0440","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.057_bib0445","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/14760584.2015.1004317","article-title":"Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives","volume":"14","author":"Whelan","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"45","key":"10.1016\/j.vaccine.2015.11.057_bib0450","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"PNAS"},{"issue":"23","key":"10.1016\/j.vaccine.2015.11.057_bib0455","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.057_bib0460","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.057_bib0465","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2015.11.057_bib0470","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.057_bib0475","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/CVI.00669-14","article-title":"A large portion of MATS negative meningococcal strains from Spain are killed by sera from adolescents and infants immunized with 4CMenB","volume":"22","author":"Abad","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0480","series-title":"Proceedings of the IPNC 2014","article-title":"Potential coverage of the BEXSERO\u00ae MenB vaccine on non-B meningococci","author":"Tomei","year":"2014"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0485","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0490","unstructured":"Joint Committee on Vaccination and Immunisation. Minutes. Available from \u3008https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation\u3009; 2015 [accessed 10.03.15]."},{"key":"10.1016\/j.vaccine.2015.11.057_bib0495","series-title":"Proceedings of the IPNC 2014","article-title":"Use of a novel serogroup B vaccine in response to two university outbreaks in the US","author":"Patel","year":"2014"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0500","series-title":"Initial dose of a multicomponent serogroup b meningococcal vaccine in the Saguenay\u2013Lac-Saint-Jean Region, Qu\u00e9bec, Canada: an interim safety surveillance report","author":"De Serres","year":"2014"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0505","unstructured":"De Serres G, Gari\u00e9py MC, Billard N, Rouleau I On behalf of INSPQ. R\u00e9sultats de la surveillance de la s\u00e9curit\u00e9 des premi\u00e8re et deuxi\u00e8me doses du vaccin contre le m\u00e9ningocoque de s\u00e9rogroupe B administr\u00e9 au Saguenay\u2014La-Saint-Jean. Available from \u3008http:\/\/www.inspq.qc.ca\/pdf\/publications\/1975_Securite_Vaccin_Meningocoque_B.pdf\u3009; 2014 [accessed 13.05.15]."},{"issue":"7","key":"10.1016\/j.vaccine.2015.11.057_bib0510","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0515","unstructured":"Australian Technical Advisory Group on Immunisation Statement. Australian Government Department of Health website. Available from \u3008http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/atagi-advice-bexsero\u3009; Updated April 2015 [accessed 11.03.15]."},{"key":"10.1016\/j.vaccine.2015.11.057_bib0520","unstructured":"The Green Book\u2013Immunisation against infectious disease. Available from \u3008https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/302904\/Green_Book_Chapter_22_v2_5.pdf\u3009; 2013 [accessed 9.03.15]."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.11.057_bib0525","first-page":"B1126","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0530","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0535","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","article-title":"Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial","volume":"32","author":"Snape","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0540","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0545","series-title":"Proceedings at the 31st Annual Meeting of European Society for Paediatric Infectious Diseases","article-title":"Two-dose toddler vaccination with investigational meningococcal b recombinant vaccine\u2014antibody persistence and response to booster at 24 months","author":"Prymula","year":"2013"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0550","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.057_bib0555","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2014.878654","article-title":"Will booster doses be required for serogroup B meningococcal vaccine?","volume":"13","author":"McQuaid","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"41","key":"10.1016\/j.vaccine.2015.11.057_bib0560","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0565","unstructured":"JCVI position statement on use of Bexsero\u00ae meningococcal B Vaccine in the UK. Available from \u3008https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf\u3009; March 2014 [accessed 25.03.15]."},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.057_bib0570","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0575","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0580","unstructured":"Letter from NHS England. Changes to the schedule for meningococcal serogroup C conjugate vaccine. Available from \u3008https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/197618\/MenC_letter_FINAL.pdf\u3009; May 2013 [accessed 27.05.15]."},{"issue":"9960","key":"10.1016\/j.vaccine.2015.11.057_bib0585","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"7385","key":"10.1016\/j.vaccine.2015.11.057_bib0590","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"Br Med J"},{"issue":"51","key":"10.1016\/j.vaccine.2015.11.057_bib0600","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1016\/j.vaccine.2013.08.008","article-title":"The role of health economic analyses in vaccine decision making","volume":"31","author":"Black","year":"2013","journal-title":"Vaccine"},{"issue":"7436","key":"10.1016\/j.vaccine.2015.11.057_bib0605","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","article-title":"Discrete choice experiments in health care","volume":"328","author":"Ryan","year":"2004","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2015.11.057_bib0610","series-title":"Proceedings of the IPNC 2014","article-title":"The Global Meningococcal Initiative, report from the second summit meeting, Cape Town, South Africa","author":"Borrow","year":"2014"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15017235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15017235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T12:39:07Z","timestamp":1653827947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15017235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0264410X15017235"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience with the meningococcal B vaccine, Bexsero\u00ae: Prospects for reducing the burden of meningococcal serogroup B disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}